Loading... (0%)
About liver disease


GENFIT is a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions to address high unmet patient needs in metabolic and inflammatory diseases, with a particular focus on the liver.

Understanding patient needs

Conscious of the importance of strategically aligning our company with patient needs, our R&D efforts are focused on contributing to bringing new medicines to market for patients with serious diseases whose treatment options are limited or non-existent.

Our rigorous drug discovery and development process, and our commitment to improving health through innovation, have resulted in the creation of a pipeline dedicated to areas where we can lead and make a significant impact.

Our lead pipeline product elafibranor (GFT505) has recently completed a positive Phase 2b study in NASH (Non-Alcoholic Steato-Hepatitis) and is currently being evaluated in the Phase 3 study RESOLVE-IT. This metabolism-related liver disease, which can progress to cirrhosis and even liver cancer, shows a dramatically increasing prevalence worldwide. Elafibranor represents a major hope for patients and their physicians, who currently have no efficient treatment for NASH.

In addition to elafibranor, our R&D pipeline relies mainly on our world-renowned scientific expertise in gene regulation and nuclear receptors.
It is comprised of multiple drug candidate research programs targeting novel mechanisms of action including the inhibition of RORγ-t.

As we strongly believe that therapies and diagnostics are interrelated and mutually supportive, our efforts are also committed to identifying and validating new biomarkers, with a particular focus on NASH.

To better answer health challenges

The scientific results obtained over the past years, and an environment of health challenges with promising markets, strengthen GENFIT in its major decisions.
Our rock-solid intellectual property framework remains the guarantee for the company’s value creation, and supports our strategic position and growth.

We are proud to be a company making patients a priority, and as a public corporation, we always strive to provide our shareholders and partners with a return that reflects an outstanding performance and rewards for those who invest in our Company.

  • Shareholders Letter
    N°8, October 2017
Corporate information
  • Analyst/Investor presentation
    October 2017
Press releases
  • GENFIT: Official Launch of the NASH Pediatric Program, following PIP and PSP Agreement by EMA and FDA
  • GENFIT: Contributing Significantly to the European LITMUS Initiative on NASH Biomarkers
  • GENFIT: Positive Outcome from the 18-month Pre-Planned Safety Review by the DSMB, in RESOLVE-IT Phase 3 Clinical Trial with Elafibranor
  • GENFIT: Risk of confusion between PPAR alpha/delta Phase 3 drug candidate elafibranor and PPAR a/d/gamma Phase 2 compound lanifibranor
  • GENFIT Reaches a Critical Milestone towards the Development of a Non-Invasive In Vitro Diagnostic (IVD) Test for NASH